CN115590813A - Loratadine oral solution and preparation method thereof - Google Patents

Loratadine oral solution and preparation method thereof Download PDF

Info

Publication number
CN115590813A
CN115590813A CN202110780489.9A CN202110780489A CN115590813A CN 115590813 A CN115590813 A CN 115590813A CN 202110780489 A CN202110780489 A CN 202110780489A CN 115590813 A CN115590813 A CN 115590813A
Authority
CN
China
Prior art keywords
solution
loratadine
oral
dissolving
oral solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110780489.9A
Other languages
Chinese (zh)
Inventor
颜廷祝
王庆娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Priority to CN202110780489.9A priority Critical patent/CN115590813A/en
Publication of CN115590813A publication Critical patent/CN115590813A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an oral solution containing loratadine, belonging to the field of pharmaceutical preparations, the oral solution of the invention comprises loratadine, a flavoring agent, a cosolvent, a stabilizer, an aromatic, a bacteriostatic agent and purified water, and the preparation method comprises the following steps: adding loratadine into a cosolvent, stirring and dissolving to obtain a solution I for later use; dissolving the bacteriostatic agent and the aromatic in water, and adding the flavoring agent to obtain a solution II for later use; dissolving the stabilizer in purified water to obtain a solution III, and mixing the solution I, the solution II and the solution III to obtain the water-soluble organic silicon dioxide. The oral solution prepared by the invention has the characteristics of improved stability, convenient administration for children and safety. The preparation process is simple, is suitable for industrial production and is convenient for market popularization.

Description

Loratadine oral solution and preparation method thereof
Technical Field
The invention relates to a loratadine oral solution and a preparation method thereof, belonging to the field of pharmaceutical preparations
Technical Field
Loratadine (loratadine), the second generation of antihistamines, is commonly used to treat allergic symptoms. One of its great properties is its non-drowsing effect compared to the first generation antihistamines. Can be used for treating allergic rhinitis, acute or chronic urticaria, allergic conjunctivitis, pollinosis and other allergic dermatoses. The antihistaminic drug has high selectivity on peripheral nerve H1 receptors, strong action and long time. Belongs to a long-acting tricyclic antihistamine, competitively inhibits a histamine H1 receptor, and inhibits allergic symptoms caused by histamine. Has no obvious anticholinergic and central inhibition effects. Can be used for relieving symptoms related to allergic rhinitis, chronic urticaria and other allergic dermatoses.
Piperidine antihistamines, derivatives of azatadine, have selective peripheral histamine H1 receptor antagonism. Its antihistaminic action is quick, strong and durable. It has stronger action than astemizole and terfenadine. The product has no sedative effect and no antimuscarinic choline effect. Has no strengthening effect on ethanol. The absorption is rapid and good after oral administration. The peak time tmax of the blood concentration is 1.5 hours. The binding rate with plasma protein was 98%. Most are metabolized in the liver, and the metabolite descarboethoxyloratadine still has antihistamine activity. The product and its metabolites are excreted from urine and feces, t1/2 is about 20 hours. It is difficult for the product and its metabolites to pass through the blood brain barrier, but it can appear in milk.
The dosage forms of loratadine selected clinically include tablets, syrup, granules and the like, and because the water solubility of loratadine is poor, the drug in solid preparations such as the tablets and the like is difficult to dissolve, so that the drug cannot achieve the due treatment effect. Liquid preparations such as syrup and oral solution have high bioavailability and are particularly suitable for children and dysphagia patients.
Chinese patent CN109498569A discloses a loratadine syrup, which comprises loratadine, a sweetening agent, propylene glycol, glycerol, disodium ethylene diamine tetraacetate, an acidity regulator, a preservative and the like; chinese patent CN105030691B discloses a loratadine granule, the components of which contain loratadine, polyethylene glycol and hydroxypropyl cellulose;
the existing loratadine preparations in China at present are mainly solid preparations and syrup preparations, and the invention provides an oral solution capable of increasing the adaptability of patients, so that the oral solution meets the administration requirements of the majority of patients.
Disclosure of Invention
The invention aims to provide a high-quality oral loratadine solution for oral administration, which overcomes the defects of the prior art, improves the degradation impurities of the preparation well, greatly improves the stability and ensures that children take the loratadine solution more safely and a preparation method thereof.
The loratadine oral solution contains loratadine, a flavoring agent, a cosolvent, a stabilizer, an aromatic, a bacteriostatic agent and purified water.
Specifically, the loratadine oral solution contains the following components in percentage by weight:
Figure BDA0003157032370000021
the second purpose of the invention is to provide a preparation method of the loratadine oral solution, which comprises the following steps:
step 1, adding loratadine into a cosolvent, stirring and dissolving to obtain a solution I for later use;
step 2, dissolving the bacteriostatic agent and the aromatic in water, and adding a flavoring agent to obtain a solution II for later use;
step 3, dissolving the stabilizer in purified water to obtain a solution III for later use
And 4, mixing the solution I, the solution II and the solution III to obtain the compound.
The cosolvent in the loratadine oral solution is propylene glycol.
The flavoring agent is one or more of glucose, maltose, sucrose and xylitol; preferably, the flavoring agent is xylitol.
The stabilizer is one or more of citric acid, glycerol, sodium alginate, pregelatinized starch, polyvidone, sodium carboxymethylcellulose, hydroxypropyl cellulose, sodium citrate, and hypromellose; preferably, the stabilizer is a mixture of citric acid and glycerol; further preferably, the dosage ratio of the citric acid to the glycerol is 7-15; most preferably, the dosage ratio of the citric acid to the glycerol is 9.6.
The aromatic is one or more of Hami melon essence, lemon essence, sweet orange essence, juicy peach essence and raspberry essence; preferably, the aromatic is raspberry essence.
The bacteriostatic agent is one or more of benzoic acid, sodium benzoate, methyl hydroxybenzoate, ethyl hydroxybenzoate, butyl hydroxybenzoate, propyl hydroxybenzoate and potassium sorbate; preferably, the bacteriostatic agent is sodium benzoate.
Further, in order to achieve the purpose of the present invention, the inventor finally obtains a technical scheme for solving the technical problems of the present invention by screening prescription compositions and dosage and optimizing process operation and process parameters through a large number of tests.
The composition and the preparation method of the loratadine oral solution are as follows:
step 1, adding loratadine into propylene glycol, stirring and dissolving to obtain a solution I for later use;
step 2, dissolving sodium benzoate and raspberry essence in water, and then adding xylitol to dissolve to obtain a solution II for later use;
and 3, dissolving citric acid and glycerol (the dosage ratio is 9.6
And 4, mixing the solution I, the solution II and the solution III to clarify the solution, uniformly stirring, adding water to full amount, and filtering.
Compared with the prior art, the technical scheme of the invention has the advantages that:
(1) The oral solution disclosed by the invention contains loratadine, a flavoring agent, a stabilizing agent and a bacteriostatic agent, and has a better dissolving effect by preferably combining auxiliary materials, especially propylene glycol, so that the solubility of loratadine can be remarkably improved.
(2) The preparation method comprises the following steps: dissolving loratadine in propylene glycol, stirring for dissolving, adding flavoring agent, aromatic agent, stabilizer and bacteriostatic agent, stirring for dissolving, homogenizing, filtering, filling, and packaging. The oral solution prepared by the invention has the characteristics of improved stability, convenient taking by children and safety. The preparation process is simple, is suitable for industrial production and is convenient for market popularization.
Detailed Description
Example 1: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000031
the specific preparation process comprises the following steps:
adding loratadine into propylene glycol, stirring and dissolving to obtain a solution I dissolved in purified water;
dissolving sodium benzoate and Hami melon essence in a proper amount of water, adding xylitol, and stirring to dissolve to obtain a solution II;
step (3), dissolving citric acid and glycerol in purified water to obtain a solution III;
and (4) slowly mixing the solutions I, II and III together while stirring to clarify the solution, uniformly stirring, adding water to full volume, measuring the pH value to be 2.5-3.0, and filtering to obtain the compound.
Example 2: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000041
preparation process reference example 1.
Example 3: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000042
the preparation process is referred to example 1.
Example 4: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000043
Figure BDA0003157032370000051
preparation process reference example 1.
Example 5: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000052
preparation process reference example 1.
Example 6: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000053
preparation process reference example 1.
Example 7: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000054
Figure BDA0003157032370000061
the preparation process is the same as in example 1.
Example 8: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000062
Preparation process reference example 1.
Example 9: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000063
the preparation process is referred to example 1.
Comparative example 1: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000064
Dissolving loratadine, sodium benzoate and Hami melon essence in a proper amount of water, adding xylitol, and stirring to dissolve to obtain a solution I;
step (3), dissolving citric acid and glycerol in purified water to obtain solution II;
and (4) slowly mixing the solutions I, II and III together while stirring to clarify the solution, uniformly stirring, adding water to full volume, measuring the pH value to be 2.5-3.0, and filtering to obtain the final product.
Comparative example 2, the following: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight:
Figure BDA0003157032370000071
the specific preparation process comprises the following steps:
dissolving loratadine, propylene glycol, sodium benzoate, hami melon essence, xylitol, citric acid, and glycerol in purified water, clarifying the solution, stirring, adding water to full volume, measuring pH to 2.5-3.0, and filtering.
Comparative example 3: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000072
The preparation process is referred to example 1.
Comparative example 4: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000073
Figure BDA0003157032370000081
The preparation process is the same as in example 1.
Comparative example 5: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000082
The preparation process is the same as in example 1.
Comparative example 6: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000083
The preparation process is the same as in example 1.
Comparative example 7: a loratadine oral solution comprises the following components (1000 mL) in percentage by weight
Figure BDA0003157032370000084
Figure BDA0003157032370000091
The preparation method comprises the following steps:
(1) Dissolving loratadine in propylene glycol;
(2) Adding glycerol and sodium benzoate into appropriate amount of water, stirring to dissolve, adding sucrose, and stirring to dissolve;
(3) Slowly adding the mixture obtained in the step (1) into the mixture obtained in the step (2) while stirring to clarify the solution, adding the honey peach essence, stirring uniformly, adding water to full volume, and performing circulating filtration
The technical effects of the embodiment are verified:
1. mouthfeel measurement
In the field of food and pharmaceutical, taste evaluation methods are mainly performed by human taste, and in recent years, although research on taste evaluation using instruments has been made, the methods are limited to technical problems and have not been widely used. Therefore, the taste evaluation research still adopts a mode of scoring the taste after people taste, combines the particularity of the preparation provided by the invention as the compound traditional Chinese medicine oral solution, and after consulting and reference documents, the invention draws up a set of scoring standard system related to the taste, as shown in table 1:
TABLE 1 oral solution taste evaluation scoring sheet
Taste grade Criterion of evaluation Scoring
1 Has poor taste, and has obvious bitter or foreign taste 1-2
2 Has good taste, and can only feel slight bitterness or off-flavor 3-4
3 Has good taste, and no bitter or off-flavor 5-6
4 Has good taste, and can only feel weak bitter taste and peculiar smell 7-8
5 Has good taste, and no bitter or foreign taste 9-10
The taste test adopts a double-blind method, and the test persons taste the tea, determine the grade and score according to the grade, wherein the full score is 10. As taste sensitivity is age-related, children are very sensitive to bitter taste, while the elderly are dull, and the total number of taste bud cells reaches the maximum in the age of 20 years, so that taste is relatively sensitive. Therefore, the age of the subject is controlled between 20 and 25 years. The trial staff in this trial recruited a total of 90 people (Lunan pharmaceutical group workers), half of each man and half of each woman. In the blank control group, which contained no active substance, other subjects should rinse with warm water before the experiment, taste each solution in sequence, each solution being in the mouth for about 10 seconds, spit out the liquid medicine, select the level of bitterness immediately, and rinse with warm water until there was no taste of the former liquid medicine in the mouth, as in example 1. SPSS17.0 is adopted to carry out statistics on related taste parameters
Table 2 oral solution taste evaluation of each example
Figure BDA0003157032370000092
Figure BDA0003157032370000101
Note: * Significant difference compared to comparative example 1
As can be seen from the results in table 2, the addition of the flavoring agents is not random, and the dosage and the type are strictly limited, while the addition of the mint flavor (comparative example 6) is all flavors but cannot achieve the same technical effect, the mouthfeel test is rather poor, and the more the flavoring agents are added, the better the dosage is. As can be seen from Table 2, comparative example 5 does not add a fragrance to the proportions of the present invention, and does not add a difference to the technical effect of the present invention.
2. And (3) testing stability test:
the stability of the oral solutions of examples 1, 2, 3 and 7 according to the invention and comparative examples 1, 2, 3, 4, 5 and 6 was determined and re-tested by 6 months of accelerated testing under conditions of 40 ℃. + -. 2 ℃ and 75%. + -. 5% relative humidity, and sampled for analysis at 0, 3 and 6 months, respectively. The contents of the relevant substances and the like are mainly observed, and the results are shown in Table 3.
TABLE 3 evaluation of stability of oral solutions of the examples
Figure BDA0003157032370000102
Figure BDA0003157032370000111
As shown in Table 3, the stability of the oral solution was good when a mixture of glycerin and citric acid was used as a stabilizer. The stability experiment result shows that the loratadine syrup is accelerated, and the characters and the content of the loratadine syrup are not obviously changed after the loratadine syrup is used for a long time of 6 months. The total related substances did not increase over 6 months in accelerated stability studies.

Claims (10)

1. The loratadine oral solution is characterized by comprising loratadine, a flavoring agent, a cosolvent, a stabilizer, an aromatic, a bacteriostatic agent and purified water.
2. The oral loratadine solution of claim 1 wherein the oral loratadine solution comprises the following ingredients, by weight:
Figure FDA0003157032360000011
3. the loratadine oral solution of claim 1 prepared by a process comprising the steps of:
step 1, adding loratadine into a cosolvent, stirring and dissolving to obtain a solution I for later use;
step 2, dissolving the bacteriostatic agent and the aromatic in water, and adding a flavoring agent to obtain a solution II for later use;
step 3, dissolving the stabilizer in purified water to obtain solution III for later use
And 4, mixing the solution I, the solution II and the solution III to obtain the compound.
4. The oral loratadine solution of any of claims 1-3 wherein the co-solvent is propylene glycol.
5. The loratadine oral solution of any of claims 1-3 wherein the flavoring agent is one or more of glucose, maltose, sucrose, xylitol; preferably, the flavoring agent is xylitol.
6. The oral loratadine solution of any of claims 1-3 wherein the stabilizing agent is one or more of citric acid, glycerin, sodium alginate, pregelatinized starch, povidone, sodium carboxymethylcellulose, hydroxypropylcellulose, sodium citrate, and hypromellose.
7. The loratadine oral solution of claim 6 wherein the stabilizer is a mixture of citric acid and glycerol.
8. The loratadine oral solution of claim 6 wherein the ratio of citric acid to glycerol is 7-15; preferably, the dosage ratio of the citric acid to the glycerol is 9.6.
9. The loratadine oral solution of any of claims 1-3 wherein the flavoring agent is one or more of cantaloupe flavor, lemon flavor, sweet orange flavor, juicy peach flavor, raspberry flavor; preferably, the aromatic is raspberry essence.
10. The loratadine oral solution of any of claims 1-3 wherein the bacteriostatic agent is one or more of benzoic acid, sodium benzoate, methylparaben, ethylparaben, butylparaben, propylparaben, potassium sorbate; preferably, the bacteriostatic agent is sodium benzoate.
CN202110780489.9A 2021-07-10 2021-07-10 Loratadine oral solution and preparation method thereof Pending CN115590813A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110780489.9A CN115590813A (en) 2021-07-10 2021-07-10 Loratadine oral solution and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110780489.9A CN115590813A (en) 2021-07-10 2021-07-10 Loratadine oral solution and preparation method thereof

Publications (1)

Publication Number Publication Date
CN115590813A true CN115590813A (en) 2023-01-13

Family

ID=84840718

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110780489.9A Pending CN115590813A (en) 2021-07-10 2021-07-10 Loratadine oral solution and preparation method thereof

Country Status (1)

Country Link
CN (1) CN115590813A (en)

Similar Documents

Publication Publication Date Title
CN101945647B (en) Pharmaceutical solutions, process of preparation and therapeutic uses
US8703156B2 (en) Liquid formulation for deferiprone with palatable taste
TWI632921B (en) Solution for oral administration
US20030055067A1 (en) Antifungal composition with enhanced bioavailability
CN111346052B (en) Desloratadine citrate disodium oral liquid preparation and preparation method and application thereof
CN100463674C (en) Oral cavity quick dissolved film containing civeran, and method for preparing the same
CN112220748B (en) Desloratadine oral liquid preparation and preparation method thereof
US9993445B1 (en) Oral solution comprising atomoxetine hydrochloride and methods thereof
CN113730336A (en) Loratadine syrup and preparation method thereof
JP6410814B2 (en) Liquid pharmaceutical composition for oral administration containing fexofenadine
CN115590813A (en) Loratadine oral solution and preparation method thereof
WONG et al. Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers
CN108434097A (en) A kind of hydrochloric triprolidine oral solution of stabilization and preparation method thereof
CN114173761B (en) Pharmaceutical composition comprising udenafil
CZ20011286A3 (en) Sertraline peroral concentrate
CN114681398A (en) Mosapride citrate syrup and preparation method thereof
CN110711172A (en) Loratadine syrup composition
WO2013062497A1 (en) Liquid pharmaceutical formulations
CN116763726A (en) Cetirizine hydrochloride oral solution and preparation method thereof
CN115715759B (en) Antihistamine suspension and preparation method thereof
CN114767677B (en) Loratadine composition and preparation method thereof
LU103368A1 (en) Pharmaceutical suspension of nilotinib
CN115177585A (en) Nimodipine oral solution and preparation method thereof
CN116492295A (en) Levocetirizine hydrochloride oral solution
CN118806761A (en) Loratadine oral preparation and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination